Overcoming Platform Inefficiencies In mAb Manufacturing

Gene Lee, Ph.D., Chief Technical Officer at AltruBio and Avril Vermunt, Sr. Director of Manufacturing Sciences and Technology at EQRx joined Matt Pillar, Chief Editor at Bioprocess Online to address how innovative biopharmas are manipulating process development and manufacturing protocols to drive efficiencies and cost controls in the face of:

• Increasingly complex molecules, 
• Regulatory scrutiny, 
• Patient accessibility and demand pressure, and 
• Shortening cash runways.

Don't have time to watch the full video? Check out these segments by topic:

• Why Efficiency Matters In mAb Manufacturing
• The Impact Of Molecular And Process Complexity On mAb Manufacturing Efficiency
• Connecting The Dots Between Discovery, Development, And mAb Manufacturing Efficiency
• The Platform Problem: Why Legacy mAb Platforms Might Be A Liability
• mAb Production Capacity, Continuous Manufacturing, & CDMO/CMO Selection
• Managing mAb Manufacturing Risk
• What's Holding Back mAb Manufacturing Efficiencies?
• Beyond The mAb: Tech, Collaboration Drive The Future Of Antibody Manufacturing

22_06_BPOL_1080p_FULL.mp4